Low dose flunixin meglumine: effects on eicosanoid production and clinical signs induced by experimental endotoxaemia in horses.
The efficacy of low doses of flunixin meglumine in reducing eicosanoid generation and clinical signs in response to experimentally induced endotoxaemia was investigated. Thromboxane B2 and 6-keto-prostaglandin F1 alpha were measured in serum and plasma by radioimmunoassay. Plasma flunixin concentrations were determined by high performance liquid chromatography and pharmacokinetic parameters derived non-compartmentally. In horses administered flunixin meglumine before endotoxin challenge, a significant suppression in plasma thromboxane B2 and 6-keto-prostaglandin F1 alpha generation was observed. Elevations in blood lactate were significantly suppressed in horses pretreated with 0.25 mg/kg bodyweight flunixin meglumine. Reduction of the clinical signs of endotoxaemia by flunixin meglumine was dose dependent. Low doses of flunixin inhibited eicosanoid production without masking all of the physical manifestations of endotoxaemia necessary for accurate clinical evaluation of the horse's status.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000818:Animals; D003002:Clonixin / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004731:Endotoxins; D006734:Horse Diseases / Q000188:drug therapy / Q000378:metabolism*; D006736:Horses; D007700:Kinetics; D007773:Lactates / Q000097:blood; D009539:Nicotinic Acids / Q000494:pharmacology*; D011897:Random Allocation; D013929:Thromboxane B2 / Q000097:blood*; D014115:Toxemia / Q000188:drug therapy / Q000378:metabolism / Q000662:veterinary*
D004731:Endotoxins; D007773:Lactates; D009539:Nicotinic Acids; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C014558:flunixin meglumine; D003002:Clonixin